Cyfendus Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to bioterrorism preparedness initiatives, prior anthrax exposure incidents, government funded vaccine programs, development of adjuvanted vaccines, military immunization needs.

The growth in the forecast period can be attributed to heightened biodefense investments, expansion of emergency response frameworks, increased public health funding, improved vaccine manufacturing capacity, stronger global security collaboration. Major trends in the forecast period include increased focus on biodefense vaccines, expansion of post exposure prophylaxis programs, government stockpiling of anthrax vaccines, rising integration of vaccines with antibiotic therapy, strengthening national emergency preparedness.

The increasing incidence of anthrax is anticipated to drive the growth of the Cyfendus market in the coming years. Anthrax incidence refers to the number of reported cases within a particular population or geographic region over a specified period, reflecting the frequency of the disease and helping public health authorities assess risk and implement preventive measures. The rise in anthrax cases is attributed to greater human and animal interaction in endemic areas, environmental factors such as disturbed soils releasing spores, and limited vaccination coverage among livestock. Cyfendus is used to provide post-exposure protection by triggering the immune system to produce antibodies against the anthrax bacteria when administered alongside antibiotics. For example, in December 2023, the World Health Organization (WHO) reported that Zambia had 684 suspected human anthrax cases as of November 2023, including four deaths, resulting in a Case Fatality Ratio (CFR) of 0.6%. These cases were distributed across 44 of the country’s 116 districts, with Sinazongwe district being the most affected, accounting for 287 cases (42% of the total) and two fatalities (50% of the total deaths). Consequently, the rising anthrax incidence is fueling the growth of the Cyfendus market.

The increase in healthcare investments is expected to further boost the growth of the cyfendus market. Healthcare investment involves allocating financial resources to sectors such as medical research, pharmaceuticals, healthcare infrastructure, and technology, aiming to improve public health outcomes and generate financial returns. The rise in healthcare investment is driven by growing demand for innovative treatments, aging populations, advancements in medical technology, and the need for efficient healthcare systems to tackle global health challenges. Such investment supports Cyfendus by funding the vaccine’s development, approval, and distribution, which is essential for enhancing public health security and addressing emerging health threats. For example, in April 2025, the Office for National Statistics reported that the UK’s healthcare expenditure reached approximately £317 billion in 2024, reflecting a 6.5% nominal increase compared with 2023. Therefore, the growing healthcare investments are contributing to the expansion of the cyfendus market.

Key companies in the Cyfendus market are concentrating on developing advanced solutions, such as post-exposure prophylactic vaccines, to strengthen immune protection, reduce infection risk, and improve response in high-risk settings. Post-exposure prophylactic vaccines are designed to stimulate the immune system to produce antibodies against Bacillus anthracis, either before or after exposure, preventing the onset of anthrax. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biotechnology firm, received U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). The CYFENDUS vaccine is indicated for post-exposure prophylaxis in individuals aged 18 to 65 following suspected or confirmed exposure to Bacillus anthracis, when administered alongside recommended antibiotics. Containing Anthrax Vaccine Adsorbed (AVA) with an additional adjuvant, CYFENDUS has shown protective immune responses in animal models of inhalational anthrax when given in two doses over 14 days, which is vital for managing large-scale public health emergencies involving anthrax.

Major companies operating in the cyfendus market are Emergent BioSolutions Inc.

North America was the largest region in the cyfendus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyfendus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyfendus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the cyfendus market by increasing costs for imported vaccine antigens, adjuvants, and sterile manufacturing materials. These impacts are more visible in regions dependent on international biodefense supply chains such as asia pacific. Government procurement programs have experienced budget pressure from higher input costs. However, tariffs have encouraged domestic vaccine manufacturing investments. This improves long term readiness for anthrax exposure response.

The cyfendus market research report is one of a series of new reports that provides cyfendus market statistics, including cyfendus industry global market size, regional shares, competitors with a cyfendus market share, detailed cyfendus market segments, market trends and opportunities, and any further data you may need to thrive in the cyfendus industry. This cyfendus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyfendus is a branded intramuscular vaccine containing anthrax vaccine adsorbed and adjuvanted, intended to protect against anthrax infections. It helps prevent anthrax caused by Bacillus anthracis by stimulating the body to produce protective antibodies. The vaccine is typically administered alongside antibiotics as part of a post-exposure prophylaxis regimen to reduce the risk of disease.

The main routes of administration for cyfendus are parenteral and oral. Parenteral refers to delivering medications or nutrients by means other than the digestive tract, usually through injection or infusion. It is used for pre-exposure prophylaxis, post-exposure prophylaxis, and special populations, and is distributed through hospital pharmacies, outpatient clinics, and specialty pharmacies.

The cyfendus market consists of sales of biodefense vaccines, antibiotics, autoinjectors, and vaccine adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.